CAMBRIDGE, MA, Alltrna, a company unlocking transfer RNA (tRNA) biology and pioneering tRNA medicines, has raised $109 million in a Series B financing.
Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA medicines to regulate the protein universe and resolve disease, announced that it has raised $109 million in a Series B financing to advance the company's platform and first drug candidates towards the clinic for a first indication in Stop Codon Disease. The financing round included the company's founder, Flagship Pioneering, and a number of top-tier investors.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
